A new UPLC-MS/MS method for the determination of irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) in mice: Application to plasma and brain pharmacokinetics

Journal of Pharmaceutical and Biomedical Analysis

Volumn 66, Issue , 2012, Pages 325-333

  Goldwirt, Lauriane ^a,b   Lemaitre, Florian ^a,b   Zahr, Noel ^a   Farinotti, Robert ^a,b   Fernandez, Christine ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b EA4123   (France)

Author keywords

Brain distribution; Carboxylesterase; Irinotecan; LC MS MS; Pharmacokinetics; SN 38

Indexed keywords

CAMPTOTHECIN; FIRTECAN; IRINOTECAN; ZINC SULFATE;

ANIMAL EXPERIMENT; ARTICLE; CALIBRATION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG STABILITY; DRUG STRUCTURE; ENZYME INACTIVATION; FEMALE; LIMIT OF QUANTITATION; LIQUID LIQUID EXTRACTION; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN; CALIBRATION; CAMPTOTHECIN; CHROMATOGRAPHY, LIQUID; FEMALE; INJECTIONS, INTRAPERITONEAL; LIMIT OF DETECTION; MICE; REPRODUCIBILITY OF RESULTS; SPECIMEN HANDLING; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; ZINC SULFATE;

EID: 84861225144     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.04.003     Document Type: Article

References (25)

1. Basili S., Moro S. Novel camptothecin derivatives as topoisomerase I inhibitors. Expert Opin. Ther. Pat. 2009, 19:555-574.
2. Sparreboom A., de Jonge M.J., de Bruijn P., Brouwer E., Nooter K., Loos W.J., van Alphen R.J., Mathijssen R.H., Stoter G., Verweij J. Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin. Cancer Res. 1998, 4:2747-2754.
3. Mathijssen R.H.J., van Alphen R.J., Verweij J., Loos W.J., Nooter K., Stoter G., Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 2001, 7:2182-2194.
4. Hosokawa M. Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules 2008, 13:412-431.
5. Tsuji T., Kaneda N., Kado K., Yokokura T., Yoshimoto T., Tsuru D. CPT-11 converting enzyme from rat serum: purification and some properties. J. Pharmacobiodyn. 1991, 14:341-349.
6. Crow J.A., Borazjani A., Potter P.M., Ross M.K. Hydrolysis of pyrethroids by human and rat tissues: examination of intestinal, liver and serum carboxylesterases. Toxicol. Appl. Pharmacol. 2007, 221:1-12.
7. Kaneda N., Nagata H., Furuta T., Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 1990, 50:1715-1720.
8. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res. 1994, 54:1431-1439.
9. Friedman H.S., Petros W.P., Friedman A.H., Schaaf L.J., Kerby T., Lawyer J., Parry M., Houghton P.J., Lovell S., Rasheed K., Cloughsey T., Stewart E.S., Colvin O.M., Provenzale J.M., McLendon R.E., Bigner D.D., Cokgor I., Haglund M., Rich J., Ashley D., Malczyn J., Elfring G.L., Miller L.L. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol. 1999, 17:1516-1525.
10. Prados M.D., Lamborn K., Yung W.K.A., Jaeckle K., Robins H.I., Mehta M., Fine H.A., Wen P.Y., Cloughesy T., Chang S., Nicholas M.K., Schiff D., Greenberg H., Junck L., Fink K., Hess K., Kuhn J. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2006, 8:189-193.
11. Fassberg J., Stella V.J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci. 1992, 81:676-684.
12. Burke T.G., Mi Z.H. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal. Biochem. 1993, 212:285-287.
13. Bardin S., Guo W., Johnson J.L., Khan S., Ahmad A., Duggan J.X., Ayoub J., Ahmad I. Liquid chromatographic-tandem mass spectrometric assay for the simultaneous quantification of Camptosar and its metabolite SN-38 in mouse plasma and tissues. J. Chromatogr. A 2005, 1073:249-255.
14. de Jong F.A., Mathijssen R.H.J., de Bruijn P., Loos W.J., Verweij J., Sparreboom A. Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2003, 795:383-388.
15. Zhang Z., Yao J., Wu X., Zou J., Zhu J. An accurate assay for simultaneous determination of irinotecan and its active metabolite SN-38 in rat plasma by LC with fluorescence detection. Chromatographia 2009, 70:399-405.
16. Ramesh M., Ahlawat P., Srinivas N.R. Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed. Chromatogr. 2010, 24:104-123.
17. Sumiyoshi H., Fujiwara Y., Ohune T., Yamaoka N., Tamura K., Yamakido M. High-performance liquid chromatographic determination of irinotecan (CPT-11) and its active metabolite (SN-38) in human plasma. J. Chromatogr. B: Biomed. Sci. Appl. 1995, 670:309-316.
18. Barilero I., Gandia D., Armand J.-P., Mathieu-Boué A., Ré M., Gouyette A., Chabot G.G. Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 1992, 575:275-280.
19. Rivory L.P., Findlay M., Clarke S., Bishop J. Trace analysis of SN-38 in human plasma by high-performance liquid chromatography. J. Chromatogr. B: Biomed. Sci. Appl. 1998, 714:355-359.
20. Guidance for Industry: Bioanalytical Method Validation, 2001, http://fda.gov/cder/guidance/index.htm.
21. Shah V.P., Midha K.K., Findlay J.W.A., Hill H.M., Hulse J.D., McGilveray I.J., McKay G., Miller K.J., Patnaik R.N., Powell M.L., Tonelli A., Viswanathan C.T., Yacobi A. Bioanalytical method validation-a revisit with a decade of progress. Pharm. Res. 2000, 17:1551-1557.
22. Kurita A., Kaneda N. High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 1999, 724:335-344.
23. Ghiasuddin S.M., Soderlund D.M. Hydrolysis of pyrethroid insecticides by soluble mouse brain esterases. Toxicol. Appl. Pharmacol. 1984, 74:390-396.
24. Younis I., Malone S., Friedman H., Schaaf L., Petros W. Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma. Cancer Chemother. Pharmacol. 2009, 63:517-524.
25. Smith N.F., Figg W.D., Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol. In Vitro 2006, 20:163-175.